{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:02:14Z","timestamp":1791666134082,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03597-x","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T11:24:44Z","timestamp":1764933884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating rituximab against cyclophosphamide or cyclosporine in idiopathic membranous nephropathy: a meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"given":"Yuping","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"2","key":"3597_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000437288","volume":"1","author":"J Xu","year":"2015","unstructured":"Xu J, Hu X, Xie J, Chen N. Management of membranous nephropathy in Asia. Kidney Dis. 2015;1(2):119\u201325. https:\/\/doi.org\/10.1159\/000437288.","journal-title":"Kidney Dis"},{"issue":"1","key":"3597_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ekir.2023.10.023","volume":"9","author":"A Destere","year":"2024","unstructured":"Destere A, Teisseyre M, Merino D, Cremoni M, Gerard AO, Crepin T, et al. Optimization of rituximab therapy in adult patients with PLA2R1-associated membranous nephropathy with artificial intelligence. Kidney Int Rep. 2024;9(1):134\u201344. https:\/\/doi.org\/10.1016\/j.ekir.2023.10.023.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3597_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-024-03912-4","volume":"25","author":"L Lu","year":"2024","unstructured":"Lu L, Cai S, Zhu H, Liu G, Wang Y, Ren P, et al. Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis. BMC Nephrol. 2024;25(1):473. https:\/\/doi.org\/10.1186\/s12882-024-03912-4.","journal-title":"BMC Nephrol"},{"issue":"4","key":"3597_CR4","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.ekir.2020.12.035","volume":"6","author":"P Gauckler","year":"2021","unstructured":"Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, et al. Rituximab in membranous nephropathy. Kidney Int Rep. 2021;6(4):881\u201393. https:\/\/doi.org\/10.1016\/j.ekir.2020.12.035.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3597_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1814427.","journal-title":"N Engl J Med"},{"issue":"4","key":"3597_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","volume":"99","author":"G Fernandez-Juarez","year":"2021","unstructured":"Fernandez-Juarez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontan F, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986\u201398. https:\/\/doi.org\/10.1016\/j.kint.2020.10.014.","journal-title":"Kidney Int"},{"issue":"9","key":"3597_CR7","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1681\/ASN.2016091022","volume":"28","author":"J van den Brand","year":"2017","unstructured":"van den Brand J, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol. 2017;28(9):2729\u201337. https:\/\/doi.org\/10.1681\/ASN.2016091022.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"3597_CR8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari F, Delbarba E, Santoro D, Gesualdo L, Pani A, Dallera N, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial. J Am Soc Nephrol. 2021;32(4):972\u201382. https:\/\/doi.org\/10.1681\/ASN.2020071091.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3597_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/1354750X.2014.993708","volume":"20","author":"AS Medrano","year":"2015","unstructured":"Medrano AS, Escalante EJ, Caceres CC, Pamplona IA, Allende MT, Terrades NR, et al. Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens. Biomarkers. 2015;20(1):77\u201383. https:\/\/doi.org\/10.3109\/1354750X.2014.993708.","journal-title":"Biomarkers"},{"issue":"2","key":"3597_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000518609","volume":"146","author":"R Ramachandran","year":"2022","unstructured":"Ramachandran R, Prabakaran R, Priya G, Nayak S, Kumar P, Kumar A, et al. Immunosuppressive therapy in primary membranous nephropathy with compromised renal function. Nephron. 2022;146(2):138\u201345. https:\/\/doi.org\/10.1159\/000518609.","journal-title":"Nephron"},{"issue":"2","key":"3597_CR11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40620-020-00781-6","volume":"34","author":"R Fenoglio","year":"2021","unstructured":"Fenoglio R, Baldovino S, Sciascia S, De Simone E, Del Vecchio G, Ferro M, et al. Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli\u2019s regimen in membranous nephropathy. J Nephrol. 2021;34(2):565\u201371. https:\/\/doi.org\/10.1007\/s40620-020-00781-6.","journal-title":"J Nephrol"},{"key":"3597_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004293.pub3","author":"Y Chen","year":"2014","unstructured":"Chen Y, Schieppati A, Chen X, Cai G, Zamora J, Giuliano GA, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2014. https:\/\/doi.org\/10.1002\/14651858.CD004293.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"3597_CR13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1440-1797.2010.01301.x","volume":"15","author":"P Kalliakmani","year":"2010","unstructured":"Kalliakmani P, Koutroulia E, Sotsiou F, Vlachojannis JG, Goumenos DS. Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy. Nephrology. 2010;15(8):762\u20137. https:\/\/doi.org\/10.1111\/j.1440-1797.2010.01301.x.","journal-title":"Nephrology"},{"issue":"3","key":"3597_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2215\/CJN.10240819","volume":"15","author":"C Trivin-Avillach","year":"2020","unstructured":"Trivin-Avillach C, Beck LH Jr. Management of membranous nephropathy after MENTOR. Clin J Am Soc Nephrol. 2020;15(3):415. https:\/\/doi.org\/10.2215\/CJN.10240819.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"3597_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09365-z","volume":"23","author":"W Xu","year":"2023","unstructured":"Xu W, Zhang Z, Li D, Dai W, Pan C, Guo M, et al. Immunosuppressive therapy for progressive idiopathic membranous nephropathy: a cost-effectiveness analysis in China. BMC Health Serv Res. 2023;23(1):361. https:\/\/doi.org\/10.1186\/s12913-023-09365-z.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"3597_CR16","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/0886022X.2017.1373130","volume":"39","author":"X Yu","year":"2017","unstructured":"Yu X, Ruan L, Qu Z, Cui Z, Zhang Y, Wang X, et al. Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety. Ren Fail. 2017;39(1):688\u201397. https:\/\/doi.org\/10.1080\/0886022X.2017.1373130.","journal-title":"Ren Fail"},{"issue":"10","key":"3597_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110376","volume":"9","author":"M Yamaguchi","year":"2014","unstructured":"Yamaguchi M, Ando M, Yamamoto R, Akiyama S, Kato S, Katsuno T, et al. Patient age and the prognosis of idiopathic membranous nephropathy. PLoS ONE. 2014;9(10):e110376. https:\/\/doi.org\/10.1371\/journal.pone.0110376.","journal-title":"PLoS ONE"},{"issue":"3","key":"3597_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000430849","volume":"130","author":"FC Fervenza","year":"2015","unstructured":"Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, et al. A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). Nephron. 2015;130(3):159. https:\/\/doi.org\/10.1159\/000430849.","journal-title":"Nephron"},{"issue":"1","key":"3597_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ndt\/gfad156","volume":"39","author":"Y Duan","year":"2023","unstructured":"Duan Y, Bai Y, Guo W, Wang L, Dai W, Guo W, et al. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial. Nephrol Dial Transplant. 2023;39(1):95\u2013102. https:\/\/doi.org\/10.1093\/ndt\/gfad156.","journal-title":"Nephrol Dial Transplant"},{"key":"3597_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108635","volume":"107","author":"E Ahmadian","year":"2022","unstructured":"Ahmadian E, Khatibi SMH, Vahed SZ, Ardalan M. Novel treatment options in rituximab-resistant membranous nephropathy patients. Int Immunopharmacol. 2022;107:108635. https:\/\/doi.org\/10.1016\/j.intimp.2022.108635.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"3597_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ekir.2016.05.002","volume":"1","author":"M Waldman","year":"2016","unstructured":"Waldman M, Beck LH Jr., Braun M, Wilkins K, Balow JE, Austin HA 3rd. Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and rituximab. Kidney Int Rep. 2016;1(2):73\u201384. https:\/\/doi.org\/10.1016\/j.ekir.2016.05.002.","journal-title":"Kidney Int Rep"},{"key":"3597_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859419","volume":"13","author":"M Teisseyre","year":"2022","unstructured":"Teisseyre M, Cremoni M, Boyer-Suavet S, Ruetsch C, Graca D, Esnault VLM, et al. Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy. Front Immunol. 2022;13:859419. https:\/\/doi.org\/10.3389\/fimmu.2022.859419.","journal-title":"Front Immunol"},{"key":"3597_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.822508","volume":"13","author":"SMS Kollner","year":"2022","unstructured":"Kollner SMS, Seifert L, Zahner G, Tomas NM. Strategies towards antigen-specific treatments for membranous nephropathy. Front Immunol. 2022;13:822508. https:\/\/doi.org\/10.3389\/fimmu.2022.822508.","journal-title":"Front Immunol"},{"issue":"6","key":"3597_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2215\/CJN.0000000000000152","volume":"18","author":"M Teisseyre","year":"2023","unstructured":"Teisseyre M, Brglez V, Cremoni M, Fernandez C, Graca D, Boyer-Suavet S, et al. Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy. Clin J Am Soc Nephrol. 2023;18(6):785. https:\/\/doi.org\/10.2215\/CJN.0000000000000152.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"3597_CR25","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","volume":"34","author":"S Boyer-Suavet","year":"2019","unstructured":"Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, et al. Rituximab bioavailability in primary membranous nephropathy. Nephrol Dial Transplant. 2019;34(8):1423\u20135. https:\/\/doi.org\/10.1093\/ndt\/gfz041.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"3597_CR26","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s10157-013-0925-2","volume":"18","author":"T Saito","year":"2014","unstructured":"Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, et al. Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial. Clin Exp Nephrol. 2014;18(5):784\u201394. https:\/\/doi.org\/10.1007\/s10157-013-0925-2.","journal-title":"Clin Exp Nephrol"},{"key":"3597_CR27","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4803-24","author":"J Usui","year":"2025","unstructured":"Usui J, Hirayama K, Kobayashi M, Suzuki S, Ebihara I, Nishiki K, et al. Randomized prospective controlled open-labeled trial of cyclosporine with\/without low-dose oral corticosteroids in idiopathic membranous nephropathy in adults with nephrotic syndrome. Intern Med. 2025. https:\/\/doi.org\/10.2169\/internalmedicine.4803-24.","journal-title":"Intern Med"},{"issue":"5","key":"3597_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1159\/000446293","volume":"43","author":"J Tao","year":"2016","unstructured":"Tao J, Zhang W, Wen Y, Sun Y, Chen L, Li H, et al. Endoplasmic reticulum stress predicts clinical response to cyclosporine treatment in primary membranous nephropathy. Am J Nephrol. 2016;43(5):348\u201356. https:\/\/doi.org\/10.1159\/000446293.","journal-title":"Am J Nephrol"},{"issue":"1","key":"3597_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ekir.2016.08.019","volume":"2","author":"R Ramachandran","year":"2017","unstructured":"Ramachandran R, Yadav AK, Kumar V, Gupta KL, Kohli HS. CD19 targeted low-dose rituximab is effective in the management of refractory phospholipase A2 receptor antibody-associated membranous nephropathy. Kidney Int Rep. 2017;2(1):89\u201390. https:\/\/doi.org\/10.1016\/j.ekir.2016.08.019.","journal-title":"Kidney Int Rep"},{"key":"3597_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1024068","volume":"13","author":"JM Hartinger","year":"2022","unstructured":"Hartinger JM, Kratky V, Hruskova Z, Slanar O, Tesar V. Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. Front Immunol. 2022;13:1024068. https:\/\/doi.org\/10.3389\/fimmu.2022.1024068.","journal-title":"Front Immunol"},{"issue":"12","key":"3597_CR31","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/ndt\/gfae084.","volume":"39","author":"M Kadatz","year":"2024","unstructured":"Kadatz M, Klarenbach S, So H, Fervenza FC, Cattran DC, Barbour SJ, et al. Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial. Nephrol Dial Transplant. 2024;39(12):2058\u201366. https:\/\/doi.org\/10.1093\/ndt\/gfae084.","journal-title":"Nephrol Dial Transplant"}],"updated-by":[{"DOI":"10.1186\/s40001-026-05121-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000}}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03597-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03597-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03597-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:38:06Z","timestamp":1789191486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03597-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3597"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03597-x","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: affiliation has been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40001-026-05121-1","URL":"https:\/\/doi.org\/10.1186\/s40001-026-05121-1","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1228"}}